LUCD · Lucid Diagnostics Inc.

Lucid Diagnostics Inc. has entered into a material definitive agreement to facilitate an underwritten public offering of its common stock. The company plans to issue and sell 18,000,000 shares at a public offering price of $1.00 per share. The transaction involves Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners and representatives for the underwriters. Under the terms of the Underwriting Agreement, the underwriters will purchase the shares at a price of $0.94 per share, representing an underwriting discount of $0.06 per share. The gross proceeds to the company are anticipated to be $18,000,000, before accounting for underwriting discounts and other offering expenses. The company has also agreed to reimburse the underwriters for certain expenses, including legal fees, up to a cap of $75,000. The offering is being conducted pursuant to the company's existing shelf registration statement on Form S-3 (File No. 333-291981), which was declared effective by the SEC on March 26, 2026. The closing of the transaction is anticipated to occur on or about April 24, 2026, subject to the satisfaction of customary closing conditions. The company intends to utilize the net proceeds from this offering for working capital and general corporate purposes. This capital raise represents a significant liquidity event for the commercial-stage diagnostics company, providing funds to support ongoing operations.